Claims for Patent: 10,744,204

Summary for Patent: 10,744,204

Title:	Conjugated compounds comprising cysteine-engineered antibodies
Abstract:	This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Inventor(s):	Changshou Gao, Godfrey RAINEY, Cuihua GAO
Assignee:	MedImmune LLC
Application Number:	US15/302,036

Details for Patent 10,744,204

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	July 27, 2016		2035-04-10

International Patent Family for US Patent 10,744,204

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015157595
United States of America	2021069341
United States of America	2018169255
Turkey	201903526
San Marino	T201900160